Does Blue Cross Blue Shield of Michigan Cover Novolog?

The direct answer, and its limits

Novolog is the brand name for insulin aspart, a rapid-acting mealtime insulin analog made by Novo Nordisk and FDA-approved for use in people with diabetes to control blood glucose around meals. It is distinct from long-acting basal insulins (such as insulin glargine) and from GLP-1 receptor agonist medications, which are a different drug class entirely. BCBSM, like most large insurers, places Novolog on a formulary tier that can shift between plan years as the insurer renegotiates rebates with manufacturers. The one fixed, non-negotiable fact here is federal: under the Inflation Reduction Act, Medicare Part D and Medicare Advantage plans must cap out-of-pocket cost for covered insulin products at $35 per month, a rule that took effect for Medicare beneficiaries starting January 2023. Everything about commercial-plan tier placement, copay amount, and prior authorization is plan-year-specific and must be verified directly with BCBSM rather than assumed from a general description.

How BCBSM's tier system works, in general

Commercial pharmacy formularies typically use a tiered structure: generics at the lowest cost-sharing tier, preferred brands on a middle tier, non-preferred brands on a higher tier, and specialty drugs on their own tier. Novolog is a brand-name insulin, so it usually lands on a preferred-brand or non-preferred-brand tier rather than the generic tier, though an authorized generic version exists and may sit lower. Where exactly a given BCBSM plan places Novolog in a specific plan year is not something a general article can state accurately, because pharmacy benefit managers renegotiate manufacturer rebates and formulary placement annually. The only reliable way to know your tier is to look up your specific plan's formulary at bcbsm.com or call the number on your member ID card.

What's stable versus what changes every year

This is the practical distinction that matters most for a BCBSM member trying to plan around Novolog costs.

Established and not plan-dependent:

• Novolog (insulin aspart) is FDA-approved as a rapid-acting insulin for glycemic control in diabetes.
• Medicare Part D and Medicare Advantage plans, including BCBSM's Medicare Advantage products, must cap out-of-pocket insulin costs at $35 per month under federal law effective January 2023.
• Michigan residents have a right to internal appeal of a coverage denial and, after exhausting internal appeals, an external review through the Michigan Department of Insurance and Financial Services (DIFS), which is binding on the insurer.
• Federally Qualified Health Centers and other 340B-eligible sites can dispense certain medications, including insulin, at reduced acquisition cost under the federal 340B Drug Pricing Program, independent of a patient's insurance status.

Plan-specific and needs same-day verification:

• Which tier Novolog sits on for your particular BCBSM commercial or Medicare Advantage plan this year.
• Whether prior authorization or step therapy applies before Novolog is covered.
• The exact copay or coinsurance dollar amount you would pay per fill.
• Whether an authorized generic or biosimilar insulin aspart is available at your pharmacy and at what price difference.
• Mail-order pricing structure for a 90-day supply.

Treating the first group as reliable background and the second group as something you must re-check every plan year is the single most useful mental model for this question.

Prior authorization and step therapy

Prior authorization requires the insurer's approval before a pharmacy dispenses a drug. Step therapy requires trying a different, usually lower-cost, medication first. Whether BCBSM applies either requirement to Novolog depends on the specific plan: some standard commercial plans do not require prior authorization for a well-established rapid-acting insulin, while some employer-customized plans or Medicare Advantage products may require it, particularly when a lower-tier authorized generic or biosimilar is available. If your plan classifies Novolog as non-preferred, you may be asked to try a preferred rapid-acting insulin first unless your physician documents a clinical reason (such as a prior adverse reaction) to bypass step therapy through a formulary exception request. Switching between rapid-acting insulin analogs is a decision that should involve your prescribing clinician, since dosing and glucose monitoring may need adjustment during a switch; specific claims about pharmacokinetic differences between products should be confirmed with your endocrinology team rather than assumed from a general article.

Novolog alternatives on the market

Novo Nordisk has offered an authorized generic version of insulin aspart, which is pharmaceutically identical to Novolog and typically sells at a lower list price than the branded product. Whether BCBSM places this authorized generic on a lower copay tier than brand Novolog varies by plan and should be confirmed with your pharmacist or BCBSM member services. Other rapid-acting insulin analogs, such as insulin lispro products, may be preferred on some BCBSM formularies. Biosimilar insulin products have also entered the U.S. market in recent years; whether a specific interchangeable biosimilar insulin aspart is available and substitutable at your pharmacy under Michigan law is a detail that needs direct verification with your pharmacist rather than a general claim here.

Costs: what's capped by law versus what you negotiate with your plan

If you have BCBSM Medicare Advantage coverage, the $35-per-month insulin cap applies to Novolog regardless of its formulary tier, because the cap is a federal requirement on the benefit itself rather than a plan choice. If you have a BCBSM commercial plan, your Novolog cost depends on your specific benefit design: the tier it sits on, whether you have met your deductible, and whether you use a preferred or mail-order pharmacy. High-deductible health plans paired with an HSA may require you to pay a negotiated but unsubsidized price until the deductible is met. Because these dollar figures change by plan and by year, this article intentionally does not state a specific commercial copay range as though it applied to every BCBSM member; your Summary of Benefits and Coverage document, available through your member portal, is the source of record.

Appeals if Novolog is denied or placed on an unfavorable tier

Common reasons for a denial include the drug not being on your specific formulary, unmet step therapy requirements, quantity limits, or a missing prior authorization. Your physician can submit a formulary exception request with clinical documentation of medical necessity, such as a prior adverse reaction to an alternative insulin. If BCBSM denies the exception, Michigan members generally have a right to a first-level internal appeal, a second-level internal appeal, and, after exhausting those, an external review through the Michigan Department of Insurance and Financial Services (DIFS), which is binding on the insurer and free to the member. Specific internal appeal timelines (for example, how many days you have to file, and how quickly BCBSM must respond) should be confirmed in your plan's Explanation of Coverage or by calling member services, since these can vary by plan type.

Other cost-reduction options worth knowing about

Novo Nordisk has offered patient assistance programs (marketed as NovoCare) for uninsured or underinsured patients, and copay savings cards for commercially insured patients; these programs generally exclude patients enrolled in Medicare or Medicaid, consistent with federal anti-kickback rules that apply to copay assistance in government programs. Patients who receive care at a Federally Qualified Health Center or other 340B-eligible site may be able to access insulin at a reduced acquisition cost through the federal 340B Drug Pricing Program, independent of insurance status. Cash prices for the same insulin can also vary meaningfully between pharmacies within the same area, which matters most for members who have not yet met a deductible.

Verification checklist: stable facts versus facts you must re-check

Use this before assuming any cost or coverage detail about Novolog on a BCBSM plan.

Stable, safe to treat as generally true without re-checking every time:

1. Novolog is FDA-approved insulin aspart, a rapid-acting mealtime insulin analog (verify current label at fda.gov if you need the exact approved indication wording).
2. Medicare Part D and Medicare Advantage plans must cap covered insulin cost-sharing at $35 per month, in effect since January 2023.
3. Michigan residents have a right to internal appeal and a binding external review through DIFS after exhausting internal appeals.
4. 340B-eligible clinics can offer reduced-cost insulin regardless of insurance status.
5. Manufacturer copay cards generally cannot be used with Medicare or Medicaid coverage.

Volatile, verify directly with BCBSM or your pharmacist before relying on it, and note the date you checked:

1. Which tier Novolog sits on for your specific plan this plan year.
2. Whether prior authorization or step therapy applies to Novolog on your plan.
3. Your exact copay or coinsurance amount per fill.
4. Whether an authorized generic or a biosimilar insulin aspart is available and what it costs on your plan.
5. Mail-order 90-day pricing and whether your plan requires a preferred mail-order pharmacy.
6. Whether pump-delivered Novolog falls under your pharmacy benefit or your durable medical equipment benefit.
7. Internal appeal filing deadlines and BCBSM's required response time for your specific plan type.

If your diabetes-related question appears in the second list, use this article and other online resources as background information before contacting BCBSM member services for definitive guidance.

Insulin pumps: a different benefit path

If you use Novolog in an insulin pump rather than by injection, coverage may fall under your plan's durable medical equipment (DME) benefit rather than the standard pharmacy benefit. DME benefits can carry different deductibles, coinsurance, and prior authorization rules than pharmacy benefits. If you use a pump, confirm with BCBSM which benefit category applies to your Novolog cartridges, since the answer affects your out-of-pocket cost calculation.

What's established, what's plausible, and what isn't established

Established: Novolog is FDA-approved insulin aspart; the federal Medicare insulin cost cap applies to Novolog regardless of tier; Michigan members have appeal and external review rights; 340B pricing exists at qualifying sites.

Plausible but plan-dependent, not something this article can state as fixed: Novolog's specific tier, copay, and prior authorization status on any individual BCBSM plan, since these are renegotiated and can change between plan years.

Not established here: any specific dollar copay range, specific percentage of patients switching insulins, or specific clinical trial outcome data comparing Novolog to a biosimilar. Precise figures of this kind require checking BCBSM's current Summary of Benefits and Coverage document and, for clinical comparisons, the peer-reviewed literature directly rather than a secondhand citation.

When to involve your care team instead of your insurer

If you are experiencing symptoms of high or low blood glucose while sorting out a coverage change, or if a switch between insulin products is being driven entirely by formulary changes rather than clinical judgment, contact your prescribing clinician before making any dosing change. Insurance coverage questions are separate from clinical safety questions, and a formulary exception request is far more likely to succeed with your physician's documentation of medical necessity than with a member-services phone call alone.

Note for editorial and medical review: the source draft for this page contained several precise clinical and survey statistics (a named clinical trial with numeric HbA1c outcomes, a physician quotation, specific percentage figures on insulin switching and rationing, and specific PubMed/journal identifiers) that could not be verified against the permitted evidence base for this rewrite and have been removed or replaced with cautious, general language. Any restoration of specific figures should be sourced directly from the cited primary literature before publication. This article has not yet received qualified medical review.